Ribupatide
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apn
Fujian Shengdi Pharmaceutical Co · Phase 3 · Active, not recruiting · Enrollment 144
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| HRS9531 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |